LY517717 + enoxaparin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Total Knee Replacement
Conditions
Total Knee Replacement, Total Hip Replacement
Trial Timeline
Dec 1, 2003 → May 1, 2005
NCT ID
NCT00074828About LY517717 + enoxaparin
LY517717 + enoxaparin is a phase 2 stage product being developed by Eli Lilly for Total Knee Replacement. The current trial status is completed. This product is registered under clinical trial identifier NCT00074828. Target conditions include Total Knee Replacement, Total Hip Replacement.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00074828 | Phase 2 | Completed |
Competing Products
11 competing products in Total Knee Replacement
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirin | Daiichi Sankyo | Approved | 85 |
| Glucagon receptor antagonist LY2409021 + Placebo | Eli Lilly | Pre-clinical | 23 |
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 85 |
| Zoledronic acid 5mg | Novartis | Approved | 85 |
| LNA043 + Placebo | Novartis | Phase 1 | 33 |
| Denosumab | Amgen | Phase 2 | 51 |
| 48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics | Sanofi | Pre-clinical | 22 |
| Exacyl® | Bayer | Phase 3 | 74 |
| Enoxaparin + Apixaban + BAY1213790 | Bayer | Phase 2 | 49 |
| etoricoxib (MK0663) 120 mg + Comparator: Placebo + etoricoxib (MK0663) 90 mg | Organon | Phase 3 | 72 |
| Ceftobiprole | Basilea Pharmaceutica | Phase 1 | 28 |